MARKET

SBBP

SBBP

Strongbridge
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.430
-0.040
-1.62%
After Hours: 2.400 -0.03 -1.23% 17:32 04/16 EDT
OPEN
2.460
PREV CLOSE
2.470
HIGH
2.460
LOW
2.371
VOLUME
598.78K
TURNOVER
--
52 WEEK HIGH
4.630
52 WEEK LOW
1.870
MARKET CAP
164.05M
P/E (TTM)
-3.0908
1D
5D
1M
3M
1Y
5Y
Global Somatostatin Receptor Type 4 Market Outlook, Industry Analysis and Prospect 2021-2026
Heraldkeepers · 2d ago
Strongbridge's Recorlev Shows Improvements in Cortisol Control In Cushing's Syndrome, Diabetes
Benzinga · 04/08 10:52
Strongbridge spikes after peer-review publication of late-stage study on hormonal disorder
Strongbridge Biopharma (SBBP) rose ~21.5% in early after hours in reaction to the company announcement of a peer-reviewed publication of its results from Phase 3 SONICS study of Recorlev (levoketoconazole)
Seekingalpha · 04/07 20:19
Strongbridge Biopharma Announces Publication Of Diabetes Subgroup Analysis From Phase 3 SONICS Study Of RECORLEV For Treatment Of Endogenous Cushing's Syndrome In Frontiers In Endocrinology
Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome in Frontiers in
Benzinga · 04/07 20:01
Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV(R) (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome in Frontiers in Endocrinology
RECORLEV (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing's Syndrome and Comorbid Diabetes Mellitus
GlobeNewswire · 04/07 20:01
Somatostatin Receptor Type 4 Market 2021 with COVID19 Impact Analysis, Product Introduction, Recent Developments, Competitive Landscape and Dynamics by 2027
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Somatostatin Receptor Type 4 market – global industry...
Market Insight Reports · 04/06 19:36
8-K: Strongbridge Biopharma plc
(EDGAR Online via COMTEX) -- 0001634432false00016344322021-03-252021-03-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/27 04:14
BRIEF-Strongbridge Biopharma PLC Files For Mixed Shelf Of Upto $200 Million
reuters.com · 03/26 10:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SBBP. Analyze the recent business situations of Strongbridge through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SBBP stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 104
Institutional Holdings: 39.98M
% Owned: 59.22%
Shares Outstanding: 67.51M
TypeInstitutionsShares
Increased
38
2.24M
New
10
1.94M
Decreased
12
2.09M
Sold Out
14
1.79M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.98%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
President/Chief Financial Officer
Richard Kollender
Chief Executive Officer
John Johnson
Other
Frederic Cohen
Other
Scott Wilhoit
Secretary
Stephen Long
Lead Director/Independent Director
Garheng Kong
Independent Director
David Gill
Independent Director
Jeffrey Sherman
Independent Director
Marten Steen
Independent Director
Hilde Steineger
Independent Director
Mårten Steen
No Data
About SBBP
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Webull offers kinds of Strongbridge Biopharma plc stock information, including NASDAQ:SBBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SBBP stock methods without spending real money on the virtual paper trading platform.